Stevanato Group profits climb as high-value solutions power margin growth

Grafa
Stevanato Group profits climb as high-value solutions power margin growth
Stevanato Group profits climb as high-value solutions power margin growth
Brie Carter
Written by Brie Carter
Share

Stevanato Group (NYSE:STVN) reported a 19% increase in annual earnings on Wednesday, as the Italian drug containment specialist successfully leveraged a record mix of high-value products to offset persistent headwinds in its engineering segment.

The Piombino Dese-based company, a critical supplier to the global pharmaceutical and biotech industries, posted full-year 2025 revenue of €1.186 billion, representing 7% growth over the prior year.

The performance was largely underpinned by the company’s "high-value solutions"—a premium portfolio including specialized syringes and vials—which accounted for 46% of total revenue for the year and reached a record 49% in the fourth quarter.

This strategic shift helped drive a 160 basis-point expansion in the adjusted EBITDA margin to 25.1%.

Fourth-quarter revenue climbed 5% to €346.5 million, with gross profit margins reaching 30.9%.

The results reflect a successful transition toward higher-margin products like the Nexa platform, which is increasingly utilized for sensitive biologics and GLP-1 obesity treatments.

While the core Biopharmaceutical and Diagnostic Solutions (BDS) segment grew 10% in the final quarter, the company’s Engineering segment continued to see anticipated declines as it undergoes a multi-year repositioning effort.

The Group also provided a detailed financial roadmap for 2026, signaling confidence in sustained demand for its injectable drug delivery solutions.

For the coming fiscal year, Stevanato expects revenue between €1.26 billion and €1.29 billion, alongside adjusted diluted earnings per share in the range of €0.59 to €0.63.

The guidance assumes a continued ramp-up of new manufacturing facilities in Indiana and Italy, which are expected to transition from being margin-dilutive to profit contributors by the end of 2026.

Despite the capital-intensive nature of its expansion, the company reported diluted earnings per share of €0.51 for the full year 2025.

Management noted that the gradual stabilization of the global vial market and the resolution of industry-wide destocking trends have provided a more predictable environment for the year ahead.

Connect with us

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.